Apimeds Pharmaceuticals (APUS) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing Apitox, a bee venom-based biologic for osteoarthritis (OA) and multiple sclerosis (MS) symptom management.

• Holds exclusive U.S. rights to Apitox through a sublicensable, royalty-bearing license from Apimeds Korea; not involved in South Korean sales.

• Apitox is a purified bee venom product, with prior clinical use and approval in South Korea for OA since 2003.

• U.S. development focuses on advanced knee OA and, in the future, MS, with plans for additional Phase III trials.

• Manufacturing is outsourced, with a proprietary process for bee venom extraction and lyophilization; U.S. market entry contingent on FDA approval.

Financial performance and metrics

• No revenue generated to date; operations funded by equity contributions, convertible notes, and related party loans.

• Net loss of $745,836 for the six months ended June 30, 2024, and $777,694 for the year ended December 31, 2023.

• Cash and cash equivalents of $63,326 as of June 30, 2024; accumulated deficit of $3,747,770.

• Operating expenses primarily consist of R&D and general and administrative costs, with significant increases in professional services and payroll in 2024.

• Auditor's report includes a going concern explanatory paragraph due to recurring losses and limited cash runway.

Use of proceeds and capital allocation

• Net proceeds from the IPO will fund a Phase III clinical trial in knee OA, initiate at least one non-registered MS study, cover manufacturing costs, and support working capital and general corporate purposes.

• Approximately $6.5 million allocated to the Phase III OA trial, $1 million to MS studies, $1 million to manufacturing, with the remainder for general expenses.

• If proceeds are less than $10 million, priorities are the OA trial, manufacturing, and regulatory requirements; additional capital may be needed.